Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan D Sniderman

Showing results (1-10 of 164) with videos related to

Pageof 17
Sort By:
Clinical Chemistry|December 13, 2018
Type III Hyperlipoproteinemia: The Forgotten, Disregarded, Neglected, Overlooked, Ignored but Highly Atherogenic, and Highly Treatable DyslipoproteinemiaAllan D Sniderman
Journal of the American College of Cardiology|April 2, 2021
Peculiar Paradoxical Results That Puzzle MeAllan D Sniderman
Diabetes Care|July 2, 2003
Non-HDL cholesterol versus apolipoprotein B in diabetic dyslipoproteinemia: alternatives and surrogates versus the real thingAllan D Sniderman
European Heart Journal|November 15, 2022
dal-GenE was negative-not positive except for COVID-19Allan D Sniderman
Lancet (London, England)|July 7, 2009
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trialAllan D Sniderman
Clinical Chemistry|September 18, 2021
ApoB vs non-HDL-C vs LDL-C as Markers of Cardiovascular DiseaseAllan D Sniderman
Circulation|December 1, 2005
Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner isAllan D Sniderman
Journal of the American College of Cardiology|September 25, 2024
Are Triglyceride-Rich Lipoprotein ApoB Particles Really 4 Times More Atherogenic Than LDL ApoB Particles?Allan D Sniderman
JAMA|December 15, 2005
Risk factors for cardiovascular disease in womenAllan D Sniderman
Annals of Clinical Biochemistry|December 31, 2009
Apolipoprotein B, diabetes and medical consensusAllan D Sniderman
Pageof 17

Showing results (1-10 of 164) with videos related to

Sort By:
Pageof 17
Clinical Chemistry|December 13, 2018
Type III Hyperlipoproteinemia: The Forgotten, Disregarded, Neglected, Overlooked, Ignored but Highly Atherogenic, and Highly Treatable DyslipoproteinemiaAllan D Sniderman
Journal of the American College of Cardiology|April 2, 2021
Peculiar Paradoxical Results That Puzzle MeAllan D Sniderman
Diabetes Care|July 2, 2003
Non-HDL cholesterol versus apolipoprotein B in diabetic dyslipoproteinemia: alternatives and surrogates versus the real thingAllan D Sniderman
European Heart Journal|November 15, 2022
dal-GenE was negative-not positive except for COVID-19Allan D Sniderman
Lancet (London, England)|July 7, 2009
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trialAllan D Sniderman
Clinical Chemistry|September 18, 2021
ApoB vs non-HDL-C vs LDL-C as Markers of Cardiovascular DiseaseAllan D Sniderman
Circulation|December 1, 2005
Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner isAllan D Sniderman
Journal of the American College of Cardiology|September 25, 2024
Are Triglyceride-Rich Lipoprotein ApoB Particles Really 4 Times More Atherogenic Than LDL ApoB Particles?Allan D Sniderman
JAMA|December 15, 2005
Risk factors for cardiovascular disease in womenAllan D Sniderman
Annals of Clinical Biochemistry|December 31, 2009
Apolipoprotein B, diabetes and medical consensusAllan D Sniderman
Pageof 17